Health
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck
An assistant conducts cancer vaccine research in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts.
Photographer: Adam Glanzman/BloombergThis article is for subscribers only.
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top executives said.
Moderna is currently in a late-stage trial for a vaccine for skin cancer. Speaking at an investor conference on Wednesday, President Stephen Hoge said the company’s cancer vaccine could be a “quite large” revenue opportunity that “could come together quite quickly.”